Corporate Presentation

This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realised. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.

The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

Disclaimer

Table of Contents

RPG Group Snapshot

RPG LS Business Overview

RPG LS Strategy

RPG LS Financial Performance

RPG LS Products Overview

TYRE

IT

INFRASTRUCTURE

SPECIALITY

USD 3 bn Global & diversified Indian business group

RPG Group: Business Portfolio

PHARMA

PLANTATIONS

POWER / TELECOM

ANCILLARY

4

Presence in key sectors of economy

Global presence in over 100 countries

Employee strength of over 20,000 across geographies

Global business of around 50%

RPG Group: Governance Structure

5

Management Board Members (MBM)

Members : Chairman, CEOs, Group HR & Group Finance

Purpose : Group level strategy decisions

Company Board of Directors

Members : Chairman, MD & Independent Directors who are experts in various fields

Purpose : Company specific strategy decisions, results review & regulatory related aspects

Business Review Board (BRB)

Members : Chairman, Group HR, Group Finance, CEO & other Key Management Personnel of the companies

Purpose : Strategic Planning, Annual Operating Plan & Business Performance Review

Centre Of Excellence (COE)

Functional COEs for critical functions such as Finance, IT, Manufacturing, Legal / Secretarial etc

Platform for Best practice sharing, leverage opportunities at group level, any common agenda discussed incl knowledge sharing

RPG Group: Corporate Social Responsibility

6

NETRANJALI

PEHLAY AKSHAR

SWAYAM

JEEVAN

SAKSHAM A multi skill development program focusing on alternate livelihoods training for women e.g. tailoring, nursing & technical skills and training and education for youth.

Program seeks to address the social need gap by imparting practical English fluency, both spoken and reading, to children thereby enabling them towards future employability.

Flagship program of RPG focusing on Preventive, Promotive , Rehabilitative and Curative Eye Care interventions ranging from children to elderly.

Program focuses on empowering women by breaking the stereotypes and paving a new path for them by giving enriched driving skills which will lead to gainful employment.

RPG Group: Corporate Social Responsibility

7

An integrated community project focusing on improving all round quality of life in the areas of clean drinking water, overall health and nutrition based interventions amongst others.

Waste Management, Awareness to public, Environment hygiene, Plastic Free Zones, Safe Agricultural Practices etc. are some of the commendable initiatives which have been undertaken by HML.

Udaan Biodiversity Park is Zensar’s flagship environment sustenance program. The 2 acre Udaan Biodiversity Park includes diverse flora and walking trails with informative signages for the benefit of students and visitors.

The National Digital Literacy Mission (‘NDLM’) has a vision to empower at least one person per household with digital literacy skills by 2020, Zensar has set up two NDLM Centres @ Hyderabad & Pune & Trained 41 students till date.

RPG Group: Key Financials

8

423 429 404

714 795

FY11 FY12 FY13 FY14 FY15

PAT (Rs Cr)

10,839

13,944

15,788

17,614 18,593

FY11 FY12 FY13 FY14 FY15

Net Revenue (Rs Cr)

943 1,121

1,250

1,690 1,732

3.6 2.8 2.9

3.5 3.6

8.7 8.0 7.9

9.6 9.3

FY11 FY12 FY13 FY14 FY15

EBITDA (Rs Cr) EBITDA / Interest EBITDA %

Note: EBITDA % is taken on Net Revenue

RPG Group: Key Financials

9

Note: 1) CEAT QIP proceeds are not considered in Net Debt 2) Average Networth is taken for FY15 after adjusting QIP proceeds of CEAT 3) ROCE is calculated by taking Operating EBIT multiplied by (1 minus tax rate @ 33%) divided by Average Capital Employed 4) ROE is calculated by taking PAT divided by Average Networth

2,648 2,705 2,836

3,284

2,830

1.0 0.9 0.9 0.8 0.6

2.8 2.4

2.3 1.9

1.6

FY11 FY12 FY13 FY14 FY15

Net Debt Net D/E (x) Net Debt / EBITDA

2,646 2,974

3,302

3,933

4,699

11% 11% 11% 13% 13%

17% 15% 13%

20% 18%

FY11 FY12 FY13 FY14 FY15

Net Worth (Rs Cr) ROCE ROE

3,122 3,274 3,384 3,410 3,483

4,162 4,468

4,752 4,954

5,285

FY11 FY12 FY13 FY14 FY15

Net Block (Rs Cr) Gross Block (Rs Cr)

Table of Contents

RPG Group Snapshot

RPG LS Business Overview

RPG LS Strategy

RPG LS Financial Performance

RPG LS Products Overview

11

RPG LS: Overview

Location: Head Office in Mumbai

Manufacturing Locations: Navi Mumbai & Ankleshwar

R&D: DSIR approved R&D centre at Navi Mumbai

Employee Base: 1150 with a PAN India presence of

Formulation field force

Listed on NSE and BSE

ICRA Rating: [ICRA] BBB+ Term Loans, Working Capital

Term Loans, Cash Credit and [ICRA]A2 for non-fund based

bank limits

API, 26%

Global Generics,

5%

Global Formulation, 70%

% of Sales

FY15 Sales Breakup

A fully integrated Pharmaceutical Organization with global footprints

12

RPG LS: Business Overview

Fermentation Technology

• Dosage Forms

• India / Emerging markets

Organic Synthesis

• Dosage Forms

• Non Branded

• Regulated markets Branded Generics

Global Generics

API

Biotech

13

Management Team

CT. Renganathan Managing Director

BM Sundaram Head – International

Business

Dr. Uday Bapat Chief Scientific Officer

Sachin Raole Chief Financial Officer

& Sr. V.P Corporate Services

Rajindrra Patkar Chief Executive

Domestic Formulations

Suchitra Tiwari Head- Regulatory

and Project Management

Rabindranath

Nandi VP- Corporate

Quality

14

Name Designation

Harsh Vardhan Goenka Chairman & Non-Executive Director

CT. Renganathan Managing Director

Sachin Nandgaonkar Non Executive Director & Non – Independent Director

C.L. Jain Non Executive & Independent Director

Dr. Lalit Kanodia Non Executive & Independent Director

Mahesh Gupta Non Executive & Independent Director

Manoj Kumar Maheshwari Non Executive & Independent Director

P.K. Mohapatra Non Executive & Independent Director

Narendra Ambwani Non Executive & Independent Director

Zahabiya Khorakiwala Non Executive & Independent Director

RPG LS: Board of Directors

15

Navi Mumbai, Maharashtra

- API Plant – EUGMP/TGA/WHO approved

Ankleshwar, Gujarat

- Formulation Plant F 1 (WHO Approved) - Formulation Plant F2 (UKMHRA

Approved) - Biotech API (WHO and Korean FDA

Approved

RPG LS: Manufacturing Facilities

16

RPG LS: Valued partnerships in API & Global Generics

17

RPG LS: Domestic Formulations - Key Brands

Main Division

(Therapies for Acute Ailments)

Impulse (Anti-Diabetic, Cardio-vascular, Anti-

Psychotic)

Nephrology (Transplant, Dialysis range for Kidney)

Oncology (Anti Cancer)

Table of Contents

RPG Group Snapshot

RPG LS Business Overview

RPG LS Strategy

RPG LS Financial Performance

RPG LS Products Overview

RPG LS: Key Financials

19

159.9

184.2 189.2

216.2 229.4 233.1

31.9 32.8 18.8 17.9 14.0 15.1

FY10 FY11 FY12 FY13 FY14 FY15

Sales (Rs Cr)

EBITDA (Rs Cr)

RPG LS: Key Financials

20

65.0

76.6 74.4

FY13 FY14 FY15

Exports (Rs Crs)

3.4% 3.3%

3.8%

FY13 FY14 FY15

R&D opex as a % to Sales

26% 24% 23%

FY13 FY14 FY15

DPCO as a % to Sales

18.7

23.8

30.0

FY13 FY14 FY15

Sales of Focus Products (Rs crs)

RPG LS: Leverage Profile

21

27

32

21

11

0 0.32

23 20 34

52

14 33

0.8 0.7 0.7

0.8

0.1

0.3

FY10 FY11 FY12 FY13 FY14 FY15

ST Debt (Rs Cr)

LT Debt (Rs Cr)

Total Debt /Equity

Table of Contents

RPG Group Snapshot

RPG LS Business Overview

RPG LS Strategy

RPG LS Financial Performance

RPG LS Products Overview

23

RPG LS: Global Formulations

Formulation Facility at Ankleshwar

cGMP Compliant Facility

Multipurpose

Caters to India & Emerging Markets

Branded generics for domestic and Emerging

markets (Africa )

Major presence in therapies like Nephrology,

Gastro-Intestinal, Pain management, Cardio-

vascular, Anti-Diabetic and Anti-Cancer

RPGLS Nephrocare ranks No. 3 among Indian

Companies operating in the Nephrology as

per AIOCD

Domestic Field Force with a strength of

about 600

24

RPG LS: Domestic Formulation- Therapies

Division Therapy Brands

RPGLS Main

Pain Management Naprosyn

Religel

Anti-infective Nufex

Qugyl

Vitamin Minmin Tonic

GI Lomofen/Lomotil

Tricane

Nephrocare

Immuno/Transplant

Azoran

Immunotec

Arpimune ME

Mofetyl

Dialysis RPO

Alfalog Tab

Division Therapy Brands

Impulse

CNS/Neuro-Psychiatry Serenace

Panicalm

Cardio-Vascular

Aldactone

Losatec

Arpitor

Anti-Diabetic Cvmet

Benclamet

Neolife Anti-Neoplastics

Frastim

Docel

Emcitaben

Chemofit

25

RPG LS: ROW Products

Product Strength Brand Name

Cyclosporine 25, 50, 100 mg Soft Gelatin Arpimune

Azathioprine 25, 50 mg Azoran

Mycophenolate Mofetil 250, 500 mg Mofetyl

Tacrolimus 0.5, 1, 5 mg Immunotac

Alfa Ketoanalogue 820 mg Alfalog

Metformin 100, 500, 700 mg Serformin

Atorvastatin 10, 20, 40, 80 mg Arpitor

Amlodipine 5, 10 mg Topdip

Aluminium Hydroxide+ Magnesium Hydroxide + Simethicone + Oxetacaine

300mg+ 150 mg+ 125 mg+ 10 mg/ml

Tricaine

Magnesium Hydroxide IP , Dried Aluminium Hydroxide, Simethicone

150 + 300 + 40 mg Siloxegene Tab

Magnesium Hydroxide Paste, Aluminium Hydroxide Paste+ Simethicone

150 + 300 + 40 mg Siloxegene Gel

26

RPG LS: Global Generics Manufacturing Facilities

GMP compliant unit at Ankleshwar

Multipurpose plant

Regulated markets

MHRA, UK approved

27

Azathioprine - Key Product in Global

Generics

Azathioprine Global Market size : $ 169 Mn

Backward Integration

State-of-the-art

Manufacturing facility

Prowess in F&D

Our Strengths

in Azathioprine

RPG LS: Global Generics (including Emerging Market of Far East and LATAM)

28

RPG LS: Global Generics Products

Lamotrigine (Tablet & OD) – 25mg, 50 mg, 100 mg

Mycophenolate Mofetil – 250 mg, 500 mg

Other Products

Products Under Development

Nicorandil – EUCTD

Sodium Valproate - EUCTD

Amlodipine - EUCTD

29

Synthetic API- Organic Synthesis Biotech API- Fermentation Technology

RPG LS: API Products

Synthetic API

Therapy Products

Immuno-suppresant

Azathioprine, Mycophenolate Sodium/Mofetil

CNS Sertraline, Risperidone, Haloperidol,

Propantheline Bromide

Gastro Intestinal Pantaprazole, Diphenoxylate HCL

Anti-Ambeitic Quinfamide

Cardiovascular Nicorandil

Anti-Convulsant Lamotrigine

Anti- Cogulant Clopidogrel Bisulphate/Besylate

Around 12 APIs produced by Organic Synthesis

High Value, Low Volume Niche APIs Creating a niche in the Oncology

segment through fermentation

technology

Biotech API

Daunorubicin

Doxorubicin

Epirubicin

Anastrazole

Letrazole

30

RPG LS: API Manufacturing Facilities

Synthetic API - 3 GMP compliant units at Navi Mumbai

MF1: Multipurpose Less regulated markets: India / ROW

MF2: Dedicated Immunosuppressant Regulated markets

MF3: Multipurpose Regulated markets

Regulatory Approvals EUGMP (HHA, Germany) TGA, Australia WHO

Fermentation Facility at Ankleshwar

WHO and KFDA certified

Oncology Facility

ROW Markets

Table of Contents

RPG Group Snapshot

RPG LS Business Overview

RPG LS Strategy

RPG LS Financial Performance

RPG LS Products Overview

RPG LS: Strategy

32

Strategy – Formulation to be the Growth Engine backward integrated with API

API –

Essentially to be a Backward Integration

Strategy to support Domestic and Global

generic products.

Direct sales of API to be focused on

LATAM and other emerging markets.

Biotech -

Geographical Expansion: Into markets like

Russia and Korea

Regulatory : Plant approved by WHO and

KFDA (for a single product). Focusing on

TGA (Australia) or European authority for

inspection during FY 16.

Global Generic –

Customer Expansion: Development

of Sertraline and Azathioprine

Product Pipeline: Building a robust

pipeline

Infrastructure: New Low RH and

Hard Gel facility being put up

Emerging Markets (Far East, LatAm,

Africa, SE Asia)

Expand geographical presence by

leveraging presence in

Immunosuppressants.

Build Product Pipeline

Global Formulations –

Thrust on Brand Building-

through Focus Brands.

Line Extensions to be

introduced in FY 16

Y O U T H A N K